Ye F
Department of Pathology, Affiliated Hospital, Guangdong Medical College, Zhanjiang.
Zhonghua Bing Li Xue Za Zhi. 1993 Apr;22(2):104-6.
A monoclonal antibody, NCL-CB11, raised against a synthetic peptide from the predicted sequence of the c-erbB-2 protein has been used immunohistochemically in a retrospective study of formalin-fixed paraffin embedded breast neoplasm biopsies. Sixty-five out of 115 infiltrating ductal carcinoma, eleven out of 15 intraductal carcinoma and seventeen out of 22 mammary Paget's diseases exhibited positive membrane staining, indicating amplification of the gene in these tumours. In infiltrating ductal carcinoma, there was a positive correlation between c-erbB-2 overexpression and axillary lymph node metastasis as well as between the overexpression and the number of mitotic figures. These results suggest that c-erbB-2 expression might be used as a predictive marker for the worse prognosis of breast carcinoma. The significance of c-erbB-2 expression in other malignant tumours and benign lesions is also discussed.
一种针对c-erbB-2蛋白预测序列合成肽产生的单克隆抗体NCL-CB11，已被用于对福尔马林固定石蜡包埋的乳腺肿瘤活检标本进行免疫组织化学回顾性研究。115例浸润性导管癌中有65例、15例导管内癌中有11例、22例乳腺佩吉特病中有17例呈现膜染色阳性，表明这些肿瘤中该基因发生了扩增。在浸润性导管癌中，c-erbB-2过表达与腋窝淋巴结转移之间以及过表达与有丝分裂象数量之间存在正相关。这些结果提示，c-erbB-2表达可能用作乳腺癌预后较差的预测标志物。文中还讨论了c-erbB-2表达在其他恶性肿瘤和良性病变中的意义。
